Market Overview

Turnstone Biologics to Present at the 2018 Wedbush PacGrow Healthcare Conference


Turnstone Biologics, a clinical-stage immuno-oncology company developing
the next generation of oncolytic viral therapies, today announced its
presentation at the upcoming investor conference:

  • 2018 Wedbush PacGrow Healthcare Conference
    Tuesday, August 14, 2018
    Time: 3:05 p.m. ET
    Sammy Farah, Ph.D., President and Chief Executive Officer

About Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company
developing the next-generation of oncolytic viral immunotherapies for
patients with a broad range of solid tumors. The company's Maraba (MG1)
oncolytic virus platform is the first to combine the tumor-killing
effects of an oncolytic virus with a tumor-targeted T-cell vaccine to
harness an individual's own immune system to attack the tumor, with the
goal of preventing recurrence and delivering a cure. Turnstone is
advancing a robust pipeline of clinical and preclinical programs.
Turnstone has initiated multiple Phase I/II clinical trials with
medicines targeting MAGEA3-expressing tumors, such as non-small cell
lung cancer, and HPV positive tumors, such as cervical and head and neck
cancers, and by 2019 expects to have multiple additional therapies in
the clinic. In 2017, Turnstone executed the largest strategic
partnership in the oncolytic virus field with AbbVie, and was named a FierceBiotech
"Fierce 15" company. The Company's lead investors include Versant
Ventures, OrbiMed, F-Prime Capital Partners and FACIT. For more
information, please visit

View Comments and Join the Discussion!